Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026)

Hims & Hers Health (HIMS) reported Total Non-Current Liabilities of $1.8 billion for Q1 2026, up 431.74% on a YoY basis from $340.0 million in Q1 2025, and up 12.85% sequentially from $1.6 billion in Q4 2025.

Hims & Hers Health (HIMS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Hims & Hers Health (HIMS) has 7 years of Total Non-Current Liabilities data on file, last reported at $1.8 billion in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities rose 431.74% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 431.74% YoY), and the FY2025 full-year result was $1.6 billion, up 594.06% from the prior year.
  • Total Non-Current Liabilities climbed to $1.8 billion in Q1 2026, from $1.6 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.8 billion in Q1 2026 to a low of $53.8 million in Q1 2022.
  • A 5-year average of $463.6 million and a median of $103.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities plunged 36.06% in 2022 and jumped 1008.31% in 2025, its largest moves.
  • Tracing HIMS's Total Non-Current Liabilities over 5 years: stood at $54.6 million in 2022, then surged by 78.02% to $97.1 million in 2023, then soared by 137.63% to $230.8 million in 2024, then soared by 594.06% to $1.6 billion in 2025, then advanced by 12.85% to $1.8 billion in 2026.
  • Business Quant data shows HIMS's Total Non-Current Liabilities at $1.8 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.6 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 88.07 Bn 86.20 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 35.75 Bn 32.01 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.84 Bn 29.90 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 27.18 Bn 23.12 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.09 Bn 20.93 Bn 648.10 Mn 599.10 Mn
6 RedHill Biopharma 21.32 Bn 21.32 Bn - 1.86 Mn
7 Viatris 19.96 Bn 18.16 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.66 Bn 16.34 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.44 Bn 12.02 Bn 785.00 Mn 6.26 Bn
10 Hims & Hers Health 6.44 Bn 5.69 Bn 396.79 Mn 1.81 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.81 Bn
Dec 31, 2025 1.60 Bn
Sep 30, 2025 1.65 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 340.01 Mn
Dec 31, 2024 230.82 Mn
Sep 30, 2024 162.21 Mn
Jun 30, 2024 118.51 Mn
Mar 31, 2024 103.60 Mn
Dec 31, 2023 97.14 Mn
Sep 30, 2023 85.30 Mn
Jun 30, 2023 69.81 Mn
Mar 31, 2023 63.48 Mn
Dec 31, 2022 54.57 Mn
Sep 30, 2022 71.63 Mn
Jun 30, 2022 60.54 Mn
Mar 31, 2022 53.81 Mn
Dec 31, 2021 85.34 Mn
Sep 30, 2021 53.72 Mn
Jun 30, 2021 52.75 Mn